Hoda Raffiei Jelodar

Hoda Raffiei Jelodar

Auto-generated profile, based on publicly available information

Hoda Raffiei Jelodar

Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2022 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
STSepideh Taghavi
Sepideh Taghavi
HJHoda Raffiei Jelodar
Hoda Raffiei Jelodar
ARAli Rafati
Ali Rafati
NNNasim Naderi
Nasim Naderi
MMMarzieh Mirtajaddini
Marzieh Mirtajaddini
SNSoroush Naseh
Soroush Naseh
Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.

11 December 2021 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
MPMohammadmehdi Peighanbari
Mohammadmehdi Peighanbari
HRHoda Raffieijelodar
Hoda Raffieijelodar
ZSZahra Shafii
Zahra Shafii
Introduction: Remote ischemic preconditioning (RIPC) is now proposed as an effective approach for preventing contrast-induced nephropathy (CIN); however, the results on its efficacy have already remained uncertain. Objectives: We aimed to assess the beneficial effects of RIPC in preventing CIN in patients undergoing coronary angiography (CA) followed by angioplasty. Patients and Methods: One hundred patients candidate for elective CA and coronary angioplasty, moderate to high risk for CIN were randomized into two groups including the group which planned for RIPC, and the control group. The overall prevalence rate of CIN was assessed and compared across the two groups. Results: The two groups were matched for demographics, cardiovascular risk profiles and laboratory parameters. The prevalence of CIN in RIPC group was 14.0% and in the control group was 26.0% indicating no statistical difference between the two groups (P = 0.105). Requiring dialysis was also planned for 0.0% and 2.0% respectively with no difference (P = 0.500). Conclusion: RIPC may not prevent CIN in patients who are candidate for invasive CA. Trial Registration: The study was approved in the Iranian Registry of Clinical Trials (identifier: IRCT20171230038144N1; https://www.irct.ir/trial/28715, ethical code: IR.IUMS. FMD.REC 1396.9311171014).